✨ Free AI Report
Sana Biotechnology, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Sana Biotechnology, Inc.
Company Research

Sana Biotechnology, Inc.: Business Overview, Financials & Competitive Analysis

Sana Biotechnology, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Hypoimmune cell therapy leader with validated clinical proof-of-concept in type 1 diabetes, strong analyst support, and capital runway to advance lead programs through 2026 IND filings. Analysts rate SANA a strong buy with 8 analysts recommending buy and 12-month price targets around $7.83-$8.71, implying significant upside. The company has.

What is Sana Biotechnology, Inc.'s industry? Sana Biotechnology, Inc. (sana.com) operates in Biotechnology - Cell & Gene Therapy. AskCyborg classifies Sana Biotechnology, Inc. under Biotechnology - Cell & Gene Therapy in its company registry.

Sana Biotechnology is a biotechnology company focused on utilizing engineered cells as medicines, developing ex vivo and in vivo cell engineering platforms for therapeutic areas including type 1 diabetes, B cell media...

7/ 10Strong

Cyborg Score thesis

Hypoimmune cell therapy leader with validated clinical proof-of-concept in type 1 diabetes, strong analyst support, and capital...

Read the full analyst-debate transcript →
Industry Biotechnology - Cell & Gene Therapy
4 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Sana Biotechnology, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Sana Biotechnology, Inc.

AskCyborg analysts argue the bull and bear cases for Sana Biotechnology, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Sana Biotechnology, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Sana Biotechnology, Inc. Overview

Pro stress-test →

Sana Biotechnology is a biotechnology company focused on utilizing engineered cells as medicines, developing ex vivo and in vivo cell engineering platforms for therapeutic areas including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company represents an emerging player in regenerative medicine with potential to address significant unmet medical needs.

Strategic Profile

Pro stress-test →

The company achieved a major validation milestone with positive 12-week clinical data for UP421 showing transplanted HIP-modified islet cells survived immune detection and produced C-peptide without immunosuppression, published in NEJM. Sana has strategically reprioritized focus toward SC451 for type 1 diabetes and SG293 for B-cell disease, suspending its allogeneic CAR T programs to concentrate resources.

Competitive Landscape

Pro stress-test →

Caribou Biosciences is noted as a major competitor in engineered cell therapy. Sana competes in the broader cell and gene therapy space against larger players including CRISPR/gene editing companies (Beam Therapeutics, Editas) and CAR-T developers (Juno, Kite). Sana has partnered with Beam Therapeutics for CRISPR Cas12b technology and Harvard College for hypoimmune cell IP, differentiating its approach through multi-platform positioning.

Industry Context

Sana Biotechnology, Inc. operates in Biotechnology - Cell & Gene Therapy.

Key facts

Founded: 2018 · Headquarters: Seattle, WA · Employees: 414 · Market cap: $1.08B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Sana Biotechnology, Inc..

  • Published NEJM data demonstrates UP421 cell survival and function without immunosuppression—a significant validation for hypoimmune engineering approach
  • Lead asset SC451 planned IND filing in 2026 with expected clinical data in 12-18 months creates near-term catalyst
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Appointed Brian Piper as CFO with 25+ years biopharma experience to manage capital and operations as pipeline advances
  • January 2026Presented at J.P. Morgan Healthcare Conference with business update from CEO Steve Harr
  • +2 moreTrack every material event for Sana Biotechnology, Inc. as it happens. Explore monitoring →
Get alerted when Sana Biotechnology, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Allogeneic CAR-T Cell TherapyEngineered cell therapy competitor in similar therapeutic areas→In Vivo Gene Editing PlatformCRISPR Cas12b partner; competing in cell engineering space→CAR-T Cell TherapyEstablished allogeneic CAR-T developer with commercial programs→Islet Cell TransplantationAlternative approach to type 1 diabetes via cell replacement→

Compare Sana Biotechnology, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Sana Biotechnology, Inc. operates in Biotechnology - Cell & Gene Therapy. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Cell & Gene Therapy research →
NEW · MCP server

Ask your AI assistant about Sana Biotechnology, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Sana Biotechnology, Inc. and its top competitor on Cyborg Score”
“What did Sana Biotechnology, Inc. do this quarter?”
“Is Sana Biotechnology, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Sana Biotechnology, Inc. do?+
Sana Biotechnology is a biotechnology company focused on utilizing engineered cells as medicines, developing ex vivo and in vivo cell engineering platforms for therapeutic areas including type 1 diabetes, B cell media...
What is Sana Biotechnology, Inc.'s Cyborg Score?+
Sana Biotechnology, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Sana Biotechnology, Inc.'s main competitors?+
Named competitors include Allogeneic CAR-T Cell Therapy, In Vivo Gene Editing Platform, CAR-T Cell Therapy, Islet Cell Transplantation. The full competitive landscape is in the AskCyborg report.
How can I get the full Sana Biotechnology, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Sana Biotechnology, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Sana Biotechnology, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biotechnology - Cell & Gene Therapy research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Cabaletta Bio, Inc.5Adicet Bio, Inc.4BrainStorm Cell Therapeutics Inc.